Collegium Pharmaceutical, Inc. (COLL)
22.02
+0.18
(+0.82%)
USD |
NASDAQ |
Oct 02, 16:00
22.05
+0.03
(+0.14%)
After-Hours: 20:00
Collegium Pharmaceutical Enterprise Value : 1.784B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.784B |
| October 01, 2026 | 1.778B |
| September 30, 2026 | 1.778B |
| September 29, 2026 | 1.791B |
| September 28, 2026 | 1.804B |
| September 25, 2026 | 1.801B |
| September 24, 2026 | 1.804B |
| September 23, 2026 | 1.798B |
| September 22, 2026 | 1.809B |
| September 21, 2026 | 1.817B |
| September 18, 2026 | 1.809B |
| September 17, 2026 | 1.796B |
| September 16, 2026 | 1.790B |
| September 15, 2026 | 1.778B |
| September 14, 2026 | 1.810B |
| September 11, 2026 | 1.808B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.828B |
| September 08, 2026 | 1.828B |
| September 04, 2026 | 1.833B |
| September 03, 2026 | 1.839B |
| September 02, 2026 | 1.858B |
| September 01, 2026 | 1.849B |
| August 31, 2026 | 1.868B |
| August 28, 2026 | 1.892B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.928B |
| August 26, 2026 | 1.963B |
| August 25, 2026 | 1.961B |
| August 24, 2026 | 1.957B |
| August 21, 2026 | 1.950B |
| August 20, 2026 | 1.964B |
| August 19, 2026 | 2.003B |
| August 18, 2026 | 1.995B |
| August 17, 2026 | 1.981B |
| August 14, 2026 | 1.986B |
| August 13, 2026 | 1.983B |
| August 12, 2026 | 1.904B |
| August 11, 2026 | 1.913B |
| August 10, 2026 | 1.953B |
| August 07, 2026 | 2.026B |
| August 06, 2026 | 2.015B |
| August 05, 2026 | 2.230B |
| August 04, 2026 | 2.230B |
| August 03, 2026 | 2.225B |
| July 31, 2026 | 2.219B |
| July 30, 2026 | 2.238B |
| July 29, 2026 | 2.248B |
| July 28, 2026 | 2.235B |
| July 27, 2026 | 2.223B |
| July 24, 2026 | 2.213B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.180B |
| Zevra Therapeutics, Inc. | 372.75M |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.05M |
| Revenue (Quarterly) | 199.88M |
| Total Expenses (Quarterly) | 214.93M |
| EPS Diluted (Quarterly) | -0.4637 |
| Gross Profit Margin (Quarterly) | 55.18% |
| Profit Margin (Quarterly) | -7.53% |
| Earnings Yield | 5.61% |
| Operating Earnings Yield | 19.43% |
| Normalized Earnings Yield | 7.326 |